Financhill
Sell
47

CLDI Quote, Financials, Valuation and Earnings

Last price:
$0.57
Seasonality move :
-36.42%
Day range:
$0.54 - $0.71
52-week range:
$0.20 - $3.89
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
3.48x
Volume:
7.4M
Avg. volume:
28.2M
1-year change:
-63.42%
Market cap:
$18.4M
Revenue:
--
EPS (TTM):
-$15.03

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
CLDI
Calidi Biotherapeutics
-- -$0.11 -- -99.21% $6.25
IMRX
Immuneering
-- -$0.42 -- -19.68% $11.42
NBY
NovaBay Pharmaceuticals
$3M -$0.88 14.03% -95.43% $0.85
NNVC
Nanoviricides
-- -$0.20 -- -26.67% --
OGEN
Oragenics
-- -- -- -- $1.00
TOVX
Theriva Biologics
-- -$0.47 -- -95.63% $7.00
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
CLDI
Calidi Biotherapeutics
$0.58 $6.25 $18.4M -- $0.00 0% --
IMRX
Immuneering
$4.17 $11.42 $150.1M -- $0.00 0% 414.71x
NBY
NovaBay Pharmaceuticals
$0.69 $0.85 $4M -- $0.00 0% 0.16x
NNVC
Nanoviricides
$1.60 -- $25.7M -- $0.00 0% --
OGEN
Oragenics
$1.41 $1.00 $1M -- $0.00 0% 0.45x
TOVX
Theriva Biologics
$0.50 $7.00 $4.1M -- $0.00 0% 0.33x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
CLDI
Calidi Biotherapeutics
-- 2.861 -- --
IMRX
Immuneering
-- 6.440 -- --
NBY
NovaBay Pharmaceuticals
4.54% -0.044 1.51% 0.75x
NNVC
Nanoviricides
-- -0.318 -- --
OGEN
Oragenics
-- 0.068 -- --
TOVX
Theriva Biologics
-- -3.388 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
CLDI
Calidi Biotherapeutics
-- -$5M -- -- -- -$7.1M
IMRX
Immuneering
-- -$15.5M -- -- -- -$14.1M
NBY
NovaBay Pharmaceuticals
$1.6M -$2.7M -334.47% -461.38% -44% -$1.3M
NNVC
Nanoviricides
-- -$2.2M -- -- -- -$2M
OGEN
Oragenics
-- -$2M -- -- -- -$2.1M
TOVX
Theriva Biologics
-- -$4.4M -- -- -- -$4.8M

Calidi Biotherapeutics vs. Competitors

  • Which has Higher Returns CLDI or IMRX?

    Immuneering has a net margin of -- compared to Calidi Biotherapeutics's net margin of --. Calidi Biotherapeutics's return on equity of -- beat Immuneering's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    CLDI
    Calidi Biotherapeutics
    -- -$0.18 --
    IMRX
    Immuneering
    -- -$0.42 --
  • What do Analysts Say About CLDI or IMRX?

    Calidi Biotherapeutics has a consensus price target of $6.25, signalling upside risk potential of 1627.12%. On the other hand Immuneering has an analysts' consensus of $11.42 which suggests that it could grow by 173.78%. Given that Calidi Biotherapeutics has higher upside potential than Immuneering, analysts believe Calidi Biotherapeutics is more attractive than Immuneering.

    Company Buy Ratings Hold Ratings Sell Ratings
    CLDI
    Calidi Biotherapeutics
    2 0 0
    IMRX
    Immuneering
    3 1 0
  • Is CLDI or IMRX More Risky?

    Calidi Biotherapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Immuneering has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock CLDI or IMRX?

    Calidi Biotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Immuneering offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Calidi Biotherapeutics pays -- of its earnings as a dividend. Immuneering pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CLDI or IMRX?

    Calidi Biotherapeutics quarterly revenues are --, which are smaller than Immuneering quarterly revenues of --. Calidi Biotherapeutics's net income of -$5M is higher than Immuneering's net income of -$15M. Notably, Calidi Biotherapeutics's price-to-earnings ratio is -- while Immuneering's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Calidi Biotherapeutics is -- versus 414.71x for Immuneering. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CLDI
    Calidi Biotherapeutics
    -- -- -- -$5M
    IMRX
    Immuneering
    414.71x -- -- -$15M
  • Which has Higher Returns CLDI or NBY?

    NovaBay Pharmaceuticals has a net margin of -- compared to Calidi Biotherapeutics's net margin of -49.65%. Calidi Biotherapeutics's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    CLDI
    Calidi Biotherapeutics
    -- -$0.18 --
    NBY
    NovaBay Pharmaceuticals
    65.26% $1.42 $1.1M
  • What do Analysts Say About CLDI or NBY?

    Calidi Biotherapeutics has a consensus price target of $6.25, signalling upside risk potential of 1627.12%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 23.19%. Given that Calidi Biotherapeutics has higher upside potential than NovaBay Pharmaceuticals, analysts believe Calidi Biotherapeutics is more attractive than NovaBay Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    CLDI
    Calidi Biotherapeutics
    2 0 0
    NBY
    NovaBay Pharmaceuticals
    1 0 0
  • Is CLDI or NBY More Risky?

    Calidi Biotherapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.681%.

  • Which is a Better Dividend Stock CLDI or NBY?

    Calidi Biotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Calidi Biotherapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CLDI or NBY?

    Calidi Biotherapeutics quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Calidi Biotherapeutics's net income of -$5M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Calidi Biotherapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Calidi Biotherapeutics is -- versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CLDI
    Calidi Biotherapeutics
    -- -- -- -$5M
    NBY
    NovaBay Pharmaceuticals
    0.16x -- $2.4M $7.7M
  • Which has Higher Returns CLDI or NNVC?

    Nanoviricides has a net margin of -- compared to Calidi Biotherapeutics's net margin of --. Calidi Biotherapeutics's return on equity of -- beat Nanoviricides's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    CLDI
    Calidi Biotherapeutics
    -- -$0.18 --
    NNVC
    Nanoviricides
    -- -$0.14 --
  • What do Analysts Say About CLDI or NNVC?

    Calidi Biotherapeutics has a consensus price target of $6.25, signalling upside risk potential of 1627.12%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 306.25%. Given that Calidi Biotherapeutics has higher upside potential than Nanoviricides, analysts believe Calidi Biotherapeutics is more attractive than Nanoviricides.

    Company Buy Ratings Hold Ratings Sell Ratings
    CLDI
    Calidi Biotherapeutics
    2 0 0
    NNVC
    Nanoviricides
    0 0 0
  • Is CLDI or NNVC More Risky?

    Calidi Biotherapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Nanoviricides has a beta of 0.882, suggesting its less volatile than the S&P 500 by 11.802%.

  • Which is a Better Dividend Stock CLDI or NNVC?

    Calidi Biotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Calidi Biotherapeutics pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CLDI or NNVC?

    Calidi Biotherapeutics quarterly revenues are --, which are smaller than Nanoviricides quarterly revenues of --. Calidi Biotherapeutics's net income of -$5M is lower than Nanoviricides's net income of -$2.2M. Notably, Calidi Biotherapeutics's price-to-earnings ratio is -- while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Calidi Biotherapeutics is -- versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CLDI
    Calidi Biotherapeutics
    -- -- -- -$5M
    NNVC
    Nanoviricides
    -- -- -- -$2.2M
  • Which has Higher Returns CLDI or OGEN?

    Oragenics has a net margin of -- compared to Calidi Biotherapeutics's net margin of --. Calidi Biotherapeutics's return on equity of -- beat Oragenics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    CLDI
    Calidi Biotherapeutics
    -- -$0.18 --
    OGEN
    Oragenics
    -- -$3.60 --
  • What do Analysts Say About CLDI or OGEN?

    Calidi Biotherapeutics has a consensus price target of $6.25, signalling upside risk potential of 1627.12%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 2027.87%. Given that Oragenics has higher upside potential than Calidi Biotherapeutics, analysts believe Oragenics is more attractive than Calidi Biotherapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    CLDI
    Calidi Biotherapeutics
    2 0 0
    OGEN
    Oragenics
    0 1 0
  • Is CLDI or OGEN More Risky?

    Calidi Biotherapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oragenics has a beta of 0.946, suggesting its less volatile than the S&P 500 by 5.446%.

  • Which is a Better Dividend Stock CLDI or OGEN?

    Calidi Biotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Calidi Biotherapeutics pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CLDI or OGEN?

    Calidi Biotherapeutics quarterly revenues are --, which are smaller than Oragenics quarterly revenues of --. Calidi Biotherapeutics's net income of -$5M is lower than Oragenics's net income of -$2.2M. Notably, Calidi Biotherapeutics's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Calidi Biotherapeutics is -- versus 0.45x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CLDI
    Calidi Biotherapeutics
    -- -- -- -$5M
    OGEN
    Oragenics
    0.45x -- -- -$2.2M
  • Which has Higher Returns CLDI or TOVX?

    Theriva Biologics has a net margin of -- compared to Calidi Biotherapeutics's net margin of --. Calidi Biotherapeutics's return on equity of -- beat Theriva Biologics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    CLDI
    Calidi Biotherapeutics
    -- -$0.18 --
    TOVX
    Theriva Biologics
    -- -$1.55 --
  • What do Analysts Say About CLDI or TOVX?

    Calidi Biotherapeutics has a consensus price target of $6.25, signalling upside risk potential of 1627.12%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1308.45%. Given that Calidi Biotherapeutics has higher upside potential than Theriva Biologics, analysts believe Calidi Biotherapeutics is more attractive than Theriva Biologics.

    Company Buy Ratings Hold Ratings Sell Ratings
    CLDI
    Calidi Biotherapeutics
    2 0 0
    TOVX
    Theriva Biologics
    1 1 0
  • Is CLDI or TOVX More Risky?

    Calidi Biotherapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.816, suggesting its less volatile than the S&P 500 by 18.373%.

  • Which is a Better Dividend Stock CLDI or TOVX?

    Calidi Biotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Calidi Biotherapeutics pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CLDI or TOVX?

    Calidi Biotherapeutics quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. Calidi Biotherapeutics's net income of -$5M is lower than Theriva Biologics's net income of -$4.3M. Notably, Calidi Biotherapeutics's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Calidi Biotherapeutics is -- versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CLDI
    Calidi Biotherapeutics
    -- -- -- -$5M
    TOVX
    Theriva Biologics
    0.33x -- -- -$4.3M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

How High Can SharkNinja Stock Go?
How High Can SharkNinja Stock Go?

If you know popular consumer appliance brands Shark and Ninja,…

Will Oklo Stock Double?
Will Oklo Stock Double?

Oklo (NYSE: OKLO) is only a year removed from its SPAC‑enabled debut,…

Why a $5 Stock Is Suddenly a Cash Machine
Why a $5 Stock Is Suddenly a Cash Machine

If you stopped tracking Grab Holdings (NASDAQ: GRAB) after its 2021 SPAC…

Stock Ideas

Buy
69
Is NVDA Stock a Buy?

Market Cap: $4T
P/E Ratio: 56x

Buy
53
Is MSFT Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 43x

Sell
42
Is AAPL Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 34x

Alerts

Buy
77
VBTX alert for Jul 15

Veritex Holdings [VBTX] is down 3.26% over the past day.

Buy
72
MNPR alert for Jul 15

Monopar Therapeutics [MNPR] is down 8.6% over the past day.

Buy
56
NBIS alert for Jul 15

Nebius Group NV [NBIS] is up 2.98% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock